VENMAX
DRUGS AND PHARMACEUTICALS LIMITED.

August 7, 2026

To,
BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.

Scrip Code: 531015

Subject: Outcome of the Meeting of the Board of Directors held on August 07, 2026

Dear Sir/Madam,

Pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that at the Meeting of the Board of Directors of **Venmax Drugs and Pharmaceuticals Limited** was held today, i.e., **Friday, August 07, 2026**, at the Registered Office of the Company, the following items were transacted:

1. **Unaudited Financial Results:**

   The Board considered and approved the Un-audited Financial Results for the Quarter ended 30th June 2026 along with Limited Review Report of the Statutory Auditors of the Company, PPKG & Co Chartered Accountants, Hyderabad.

   Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the copy of the approved Unaudited Standalone Financial Results along with Limited Review Report for the said Quarter for your information and records.

2. **Forfeiture of Partly Paid-up Share Warrants:**

   The Board considered and approved the forfeiture of **7,80,001 (Seven Lakhs Eighty Thousand One)** partly paid-up Convertible Share Warrants allotted on a preferential basis on **March 20, 2025**, on account of non-payment of the balance warrant subscription amount within the period prescribed under the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and the terms of issue.

   The Board noted that the Company had allotted **1,00,25,000 Convertible Share Warrants** on a preferential basis on **March 20, 2025** at an issue price of **₹20/- (Rupees Twenty only) per warrant**. As per the terms of issue, **25% of the issue price (₹5/- per warrant)** was received at the time of allotment and the balance **75% of the issue price (₹15/- per warrant)** was payable by the respective warrant holders at the time of exercising the option for conversion into equity shares within the period prescribed under the applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Out of the total **1,00,25,000** warrants allotted, the Company received the balance subscription amount in respect of **92,44,999** warrants, which were subsequently converted into an equivalent number of fully paid-up equity shares of the Company.

However, in respect of the remaining **7,80,001** warrants, the respective warrant holders failed to remit the balance subscription amount within the stipulated period. The Company had issued demand letters, reminder notices and other communications from time to time, providing sufficient opportunity to the concerned warrant holders to make payment of the balance subscription amount and informing them that failure to make such payment would result in forfeiture of the warrants in accordance with the terms of issue. Despite such opportunities, the concerned warrant holders failed to make the payment within the prescribed timeline.

Accordingly, pursuant to the terms of issue, the provisions of the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the Board approved the forfeiture of the said **7,80,001** partly paid-up Convertible Share Warrants. Consequently, the upfront subscription amount aggregating to **₹39,00,005/-**, being **25% of the issue price already paid by the warrant holders**, stands forfeited and retained by the Company.

The particulars of the forfeited warrants are as under:

Particulars	Details
Date of Original Allotment	March 20, 2025
Total Warrants Forfeited	7,80,001
Issue Price per Warrant	₹20/-
Initial Subscription Amount Received (25%)	₹5/- per warrant
Balance Amount Payable (75%)	₹15/- per warrant
Reason for Forfeiture	Non-payment of the balance subscription amount within the prescribed period
Total Amount Forfeited and retained by the Company	₹39,00,005/-

The details of the warrant holders whose warrants have been forfeited are as under:

Sl. No	**Name of Warrant Holder**	**No. of Warrants Forfeited**	**Amount Forfeited (₹)**
1	Trupti Uday Khanapurkar	33,334	1,66,670

2	WCA Services Private Limited	96,667	4,83,335
3	Hitesh Surendrakumar Loonia	2,50,000	12,50,000
4	Vibhu Maurya	2,50,000	12,50,000
5	Mohit Loonia	1,50,000	7,50,000
Total		**7,80,001**	**39,00,005**

Consequent to the aforesaid forfeiture, the said warrants stand cancelled and the Company shall be entitled to deal with such forfeited warrants in accordance with the applicable provisions of the Companies Act, 2013, the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and other applicable laws.

The Financial Results are also available on the website of the Company at www.venmaxdrugs.com and on the website of BSE www.bseindia.com.

The Board Meeting commenced at 4:00 P.M. and concluded at 04:40 P.M.

Kindly take the above information on record and oblige.

Thanking You

Yours Faithfully

for **Venmax Drugs & Pharmaceuticals Limited**

Sadhanala Venkata Rao
Digitally signed by Sadhanala Venkata Rao
Date: 2026.08.07 16:48:05 +05'30'

Venkata Rao Sadhanala
Managing Director
DIN: 02906370

VENMAX
DRUGS AND PHARMACEUTICALS LIMITED.

Annexure -I

Statement of Financial Results for the Quarter ended 30th June 2026

(RS. IN LAKHS)

	Particulars	Quarter ended			Year Ended	
		30/06/2026 (Unaudited)	**31/03/2026 (Audited)**	**30/06/2025 (Unaudited)**	**31/03/2026 (Audited)**	**31/03/2025 (Audited)**
-	**Income**					
I	Revenue from operations	247.94	394.39	121.03	802.49	80.73
II	Other income	0.03	9.21	-	16.04	105.32
	Total Revenue (I+II)	**247.96**	**403.60**	**121.03**	**818.53**	**186.05**
II	**Expenses**					
	Cost of materials consumed	-	-		-	-
	Purchases of Stock-in-Trade	341.81	306.32	112.25	822.27	85.21
	Change of Inventory	(116.99)	57.27	(3.18)	(94.13)	(5.75)
	Employee benefits expense	5.42	5.43	4.65	19.67	4.00
	Finance costs	-	-	0.01	-	0.08
	Depreciation and amortization expense	0.13	0.10	0.10	0.40	0.64
	Other expenses	5.94	24.05	3.46	42.64	103.28
	Total expenses	**236.31**	**393.16**	**117.29**	**790.84**	**187.47**
III	Profit before Exceptional items and tax	11.65	10.44	3.74	27.70	(1.41)
	Exceptional Items					
	Profit / (Loss) before tax	**11.65**	**10.44**	**3.74**	**27.70**	**(1.41)**
IV	Tax expense:					
	Current tax	-	(0.28)	-	2.88	-
	Deferred tax	(0.01)	(0.00)	-	(0.01)	(0.36)
	Profit/(loss) for the period from continuing operations	**(0.01)**	**(0.28)**	**-**	**2.88**	**(0.36)**
	Profit/(loss) from discontinued operations					
	Tax expense of discontinued operations					
	Profit/(loss) from Discontinued operations (After tax)					

V	**Profit/(loss) for the year**	**11.66**	**10.72**	**3.74**	**24.82**	**(1.05)**
	Other Comprehensive Income A (i) Items that will not be reclassified to Profit or Loss (ii) Income tax relating to items that will not be reclassified to Profit or Loss B (i) Items that will be reclassified to Profit or Loss (ii) Income tax relating to items that will be reclassified to Profit or Loss Total Comprehensive Incoe for the period (Comprising Profit / (Loss)) and Other Comprehensive Income for the period)					
VI	Earnings per Equity Share - Basic and Diluted	**0.10**	**0.205**	**0.07**	**0.21**	**(0.02)**

Notes to Accounts:

1. The above unaudited financial results of VENMAX DRUGS AND PHARMACEUTICALS LIMITED for the Quarter ended 30th June 2026 as reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on 7th August, 2026. The Statutory Auditors of the Company have carried out a Limited Review on standalone financial results and expressed an unmodified conclusion thereon.

2. The Financial results have been prepared in accordance with applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 read with (Indian Accounting Standard) Rules, 20105 (Ind AS), and other accounting principles generally accepted in India and guidelines issued by Securities and Exchange Board of India (SEBI).

3. The Company operates in single segment. Accordingly, disclosures under Indian Accounting Standards (Ind AS) 108 on operating segments are not applicable to the Company.

4. Previous period figures have been reclassified and regrouped wherever considered necessary to confirm to the current period figures.

Place: Hyderabad
Date: 7th August, 2026

For Venmax Drugs and Pharmaceuticals Limited

Sadhanala Venkata Rao
Digitally signed by Sadhanala Venkata Rao
Date: 2026.08.07 16:48:39 +05'30'

Venkata Rao Sadhanala
Managing Director
DIN: 02906370

VENMAX
DRUGS AND PHARMACEUTICALS LIMITED.

Statement of Assets and Liabilities as at 30th June 2026

Particulars	Notes	As at 30th June 2026, Unaudited	As at 31st March 2026, Audited
I.ASSETS			
(1) Non-Current Assets			
(a) Property, Plant and Equipment	3	4.09	3.65
(b) Capital Work-In-Progress			
(c) Intangible Assets			
(d) Financial Assets			
(i) Non-Current Investments			
(ii) Trade and Other Receivables			
(iii) Long Term Loans and Advances			
(d) Deferred Tax Assets (Net)			
(e) Other Non-Current Assets			
Non-Current Assets		**4.09**	**3.65**
(2) Current Assets			
(a) Inventories	4	216.87	99.88
(b) Financial Assets			
(i) Investments			
(ii) Trade and Other Receivables	5	161.03	143.00
(iii) Cash and Cash Equivalents	6	82.19	122.36
(iv) Other Financial Assets	7	1183.22	734.97
(c) Other Current Assets	8	35.24	516.14
Current Assets		**1678.55**	**1616.36**
Total Assets		**1682.64**	**1620.02**
I. EQUITY AND LIABILITIES			
(1) Equity			
(a) Share Capital	9	1158.29	1158.29
(b) Other Equity	10	342.49	253.33
Equity		**1500.78**	**1411.62**
(2) Non-Current Liabilities			
(a) Financial Liabilities			
(i) Long Term Borrowings	11(a)	0.00	4.96
(b) Provisions			
(c) Deferred Tax Liabilities (Net)	12	0.09	0.10
(d) Other Non-current Liabilities			
Non-Current Liabilities		**0.09**	**5.06**

(3) Current Liabilities			
(a) Financial Liabilities			
- Short term Borrowings	11(b)	21.08	28.13
-Other Financial Liabilities	13	1.58	1.81
(i) Trade Payables			
Micro and small enterprises			
Other than micro and small enterprises	14	153.25	167.73
(b) Short Term Provisions	15	3.81	3.81
(c) Other Current Liabilities	16	2.05	1.86
Current Liabilities		**181.8**	**203.34**
Total Liabilities		**1682.64**	**1620.02**

Place: Hyderabad
Date: 7th August, 2026

For Venmax Drugs and Pharmaceuticals Limited

Sadhanala Venkata Rao
Digitally signed by Sadhanala Venkata Rao
Date: 2026.08.07 16:49:03 +05'30'

Venkata Rao Sadhanala
Managing Director
DIN: 02906370

VENMAX
DRUGS AND PHARMACEUTICALS LIMITED.

Cash Flow Statement for the Quarter Ended 30th June 2026

PARTICULARS	As at June 30, 2026, Unaudited	As at Mar 31, 2026, Audited
A) CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit as per Profit & Loss A/c	11.65	27.70
Adjustment for:		
Depreciation	0.13	0.40
Other comprehensive income	-	-
Loss on Sale / Discard of Intangible Assets (Net)	-	-
Net Operating Profit Before Working Capital	**11.79**	**28.10**
Changes		
Adjustment for :		
Trade & Other Receivables	(18.02)	(47.75)
Changes in inventory	(116.99)	(94.13)
Other Current Assets	480.91	(513.47)
Trade Payables	(14.48)	104.86
Other Financial liabilties	(0.23)	0.96
Other current liabilties	0.19	(4.42)
Provisions	-	3.11
Other Financial Asset	(448.25)	(573.97)
Net Cash from Operating Activities	**(105.09)**	**(1096.73)**
Direct taxes paid		2.87
Net Cash from Operating Activities	**(105.09)**	**(1099.60)**
B) CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(0.58)	-
Sale of Fixed assets	-	-
Net Cash from Investing Activites	**(0.58)**	**-**
C) CASH FLOW FROM FINANCING ACTIVITIES		
Share application money pending allotment	77.50	951.60
Share Application money pending allotment money returned		(6)
Proceeds from long/short term borrowings	(12.01)	28.13
Repayment of borrowings		
Net Cash from Financing Activites	**65.49**	**973.73**

Reg Office: Sy. No. 115, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Picket, Hyderabad – 500009
CIN: L24230TG1988PLC009102 GSTIN: 36AAACY1073C3ZM

E-mail: venmaxdrugs@gmail.com

Net Increase in Cash & Cash Equivalents	(40.17)	(125.87)
Add: Opening Cash & Cash Equivalents	122.36	248.24
Cash and Cash equivalents at the end of the year	**82.19**	**122.36**

Place: Hyderabad
Date: 7th August, 2026

For Venmax Drugs and Pharmaceuticals Limited

Sadhanala Venkata Rao
Digitally signed by Sadhanala Venkata Rao
Date: 2026.08.07 16:49:21 +05'30'

Venkata Rao Sadhanala
Managing Director
DIN: 02906370

PPKG & Co
Chartered Accountants

Batgach
& AFFILIATES
A NETWORK APPROVED BY ICAI

Independent Auditor's Limited Review Report on the Quarterly Unaudited Financial Results of The Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Venmax Drugs and Pharmaceuticals Limited
Hyderabad

We have reviewed the accompanying Statement of unaudited financial results of Venmax Drugs and Pharmaceuticals Limited (the "Company") for the quarter ended 30th June, 2026 (the "Statement") attached herewith, being submitted by the Company, pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the Listing Regulations").

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed necessary procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Head Office: # 5-8-352, 701, 7th Floor, Raghav Ratna Towers, Chirag Ali Lane, Abids, Hyderabad - 500 001.
Satellite Office: 431, Workfella Cyber Crown, Beside TCS, Near Raidurg Metro Station, Madhapur, Hyderabad - 500 081.
Branch Office: Rainbow Complex, Kandulvari Street, One Town Vijayawada - 520 001.
Ph : 2320 5049, 91-40- 3516 5761, 6613 2176, 3516 5760 | E-mail : giri@ppkg.com | www.batgach.com
Associate Office at : •AHMEDABAD •BANGALORE • CHENNAI • DELHI • GUWAHATI • JAIPUR • JODHPUR • INDORE • KOLKATA •MUMBAI • PATNA • TRIVANDRUM •SILCHAR (ASSAM)

Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PPKG And CO
Chartered Accountants
FRN: 0009655S

PPKG & CO. ★ HYDERABAD ★ Chartered Accountants

GIRDHARI LAL TOSHNIWAL
(Partner)
M.No-205140

Udin No: 26205140JYOLEU3983

Place: Hyderabad
Date: 07/08/2026